KromaTiD Secures Series A Funding to Advance Its Directional Genomic Hybridization (dGH™) Platform

On August 15, 2019, VCBeat (WeChat Official Account: vcbeat) learned that KromaTiD, a manufacturer of the directed genomic hybridization (dGH™) platform headquartered in Longmont, Colorado, had completed its Series A financing. The round was led by First Capital Ventures, with the amount undisclosed.

This round of financing will be used to advance the development of the company’s platform, enhance its performance and expand its capacity, including further optimization of AI-powered key image analysis capabilities.

It is reported that KromaTiD secured $50,000 in debt financing on September 10, 2013, with the investing institution undisclosed.

Led by CEO Dr. Christopher Tompkins, KromaTiD is advancing its directed genomic hybridization (dGH™) platform, which provides tools for assessing the success and quality of editing at the cellular level. The company focuses on CRISPR and other gene-editing technologies. Launched in 2013, KromaTiD’s products and services have paved the way for deeper insights into genetic disorders, including cancer and developmental disorders.

KromaTiD’s directed Genomic Hybridization™ (dGH) technology combines bioinformatics-driven design of unique single-stranded synthetic probes with a strand-specific hybridization strategy, making it the only genomics method capable of detecting DNA sequence, location, and orientation in a single assay.

By leveraging advanced genomic and bioinformatics strategies, targeted genomic hybridization can be effectively applied to projects involving thousands of samples.

With its ability to resolve very small inversions and translocations, dGH technology can be used for targeted studies, rapidly providing data on novel or variable rearrangements to meet the needs of patient screening or target validation. If a comprehensive genetic profile is required, dGH can be paired with NGS on the same sample to construct a complete mutational landscape.

For inversions or translocations with known breakpoints, targeted dGH assays are an effective method for screening large populations or libraries, and can be multiplexed and automated to provide data on multiple aberrations in the same test.

First Capital Ventures is a Denver-based venture capital firm serving as the general partner and fund manager for Viridis Fund I. The firm invests in innovative technologies that disrupt industries, or in emerging technology companies within nascent sectors that are reshaping markets. It focuses on entry and exit strategies, aiming to realize exits within 24 to 36 months.

(Compiled by Tan Jiulin)